Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials.

Thomas, Xavier; Elhamri, Mohamed; Deloire, Alexandre; Heiblig, Maël

Thomas, Xavier; Elhamri, Mohamed; Deloire, Alexandre; Heiblig, Maël.

Afiliação

Thomas X; Department of Clinical Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.
Elhamri M; Department of Clinical Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.
Deloire A; Department of Clinical Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.
Heiblig M; Department of Clinical Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.

Expert Opin Emerg Drugs ; 27(2): 169-185, 2022 06.

Article em En | MEDLINE | ID: mdl-35749672

Assuntos

Leucemia Mieloide Aguda; Adulto; Anticorpos Monoclonais/efeitos adversos; Ensaios Clínicos Fase II como Assunto; Humanos; Imunoterapia; Leucemia Mieloide Aguda/tratamento farmacológico; Estudos Prospectivos

Palavras-chave

Acute myeloid leukemia; CAR-T cells; bi-specific recombinant antibodies; drug conjugate antibodies; immune checkpoint treatments; monoclonal antibodies; radio-conjugated antibodies; unconjugated antibodies

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google